Plasma interleukin-2 levels and thyroid function in elderly patients with nonthyroidal illness.

Arch Gerontol Geriatr

Department of Internal Medicine, Division of Internal Medicine and Metabolic Diseases, School of Medicine, University of Messina, Policlinico Universitario, Via Consolare Valeria, I-98124, Messina, Italy.

Published: December 2009

To determine whether interleukin-2 (IL-2) plasma concentrations are modified in patients with nonthyroidal illness (NTI) and thyroid function alterations, we measured plasma concentrations of T(3), T(4), free T(3) (FT(3)), free T(4) (FT(4)), TSH, and IL-2 in 34 elderly NTI patients and in 25 age- and sex-matched healthy controls. IL-2 was detectable in 11 of the 34 patients. Patients with detectable IL-2 plasma levels had significantly lower plasma T(3) and FT(3) concentrations when compared to those with undetectable IL-2. Moreover, IL-2 plasma levels were positively correlated to reverse T(3) (rT(3)), (r(S)=0.67, P<0.05), and negatively to FT(3) concentrations (r(S) =-0.64, P<0.05). These observations suggest that some of the alterations in thyroid hormone levels seen in NTI are associated with elevated plasma concentrations of IL-2.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0167-4943(98)00010-7DOI Listing

Publication Analysis

Top Keywords

il-2 plasma
12
thyroid function
8
patients nonthyroidal
8
nonthyroidal illness
8
plasma concentrations
8
plasma levels
8
plasma
6
il-2
6
patients
5
plasma interleukin-2
4

Similar Publications

Background: Understanding the immunopathogenesis of COVID-19 has yielded valuable insights into predicting adverse outcomes-particularly mortality. However, significant gaps persist in our comprehension of the complex interplay among the proposed pathophysiological mechanisms. Here, we aim to investigate the immunological factors associated with mortality in critically ill, unvaccinated COVID-19 patients admitted to the intensive care unit (ICU).

View Article and Find Full Text PDF

Background: Oncolytic viruses (OVs) are promising immunotherapeutics to treat immunologically cold tumors. However, research on the mechanism of action of OVs in humans and clinically relevant biomarkers is still sparse. To induce strong T-cell responses against solid tumors, TILT-123 (Ad5/3-E2F-d24-hTNFa-IRES-hIL2, igrelimogene litadenorepvec) was developed.

View Article and Find Full Text PDF

Background: Mitochondria-driven oxidative/redox stress and inflammation play a major role in chronic kidney disease (CKD) pathophysiology. Compounds targeting mitochondrial metabolism may improve mitochondrial function, inflammation, and redox stress; however, there is limited evidence of their efficacy in CKD.

Methods: We conducted a pilot randomized, double-blind, placebo-controlled crossover trial comparing the effects of 1200 mg/day of coenzyme Q10 (CoQ10) or 1000 mg/day of nicotinamide riboside (NR) supplementation to placebo in 25 people with moderate-to-severe CKD (estimated glomerular filtration rate [eGFR] <60mL/min/1.

View Article and Find Full Text PDF

The impact of human cytomegalovirus (HCMV) infection on the mid- and long-term balance between pro-inflammatory and anti-inflammatory cytokines among kidney transplant recipients (KTRs) remains unclear. We measured plasma levels of 12 Th1/Th2-type cytokines (granulocyte-macrophage colony-stimulating factor, interferon-γ, interleukin [IL]-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12p70, IL-13, IL-18 and tumor necrosis factor-α) in a cohort of 290 KTRs at four time points through month 12 after transplantation. Cytokine levels at each point were compared according to the previous documentation of HCMV replication by two approaches: "cumulative exposure" from the time of transplantation and "recent exposure" within the 2-3 months preceding cytokine assessment.

View Article and Find Full Text PDF

Retrovirus-based manufacturing of chimeric antigen receptor-modified T cells for cancer therapy research.

Methods Cell Biol

January 2025

Division of Clinical Pharmacology, Department of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany; German Cancer Consortium (DKTK), Partner Site Munich, A Partnership Between the DKFZ Heidelberg and LMU University Hospital, Munich, Germany; Einheit für Klinische Pharmakologie (EKLiP), Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), Neuherberg, Germany. Electronic address:

Treatment with autologous chimeric antigen receptor (CAR)-modified T cells can achieve outstanding clinical response rates in heavily pretreated patients with B and plasma cell malignancies. However, relapses occur, and they limit the efficacy of this promising treatment approach. The complex GMP-compliant production and high treatment costs cause that CAR T cells cannot yet be used in a broad population.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!